1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 2: MR findings in the amygdala/hippocampus and the time interval from the onset of neurological symptoms
Time of Imaging with Reference to Symptom Onset Imaging Findings in the Amygdala/Hippocampus
Plain CT T1WI T2WI FLAIR DWI ADC Value Gd-T1WI Others on MR
Abnormal findings Low High High High Reduction Abnormal enhancement Atophic change
Early period, days 1–2 (n = 4 patients) 0/3 (0%) 2/4 (50%) 2/4 (50%) 2/3 (67%) 2/2 (100%) 2/2 (100%) 0/2 (0%) 0/4 (0%)
Middle period, days 3–30 (n = 4 patients) 5/6 (83%) 4/6 (67%) 5/6 (83%) 3/5 (60%) 1/3 (33%) 0/2 (0%) 2/6 (33%)
Late period, days 31+ (n = 4 patients) 0/4 (0%) 0/4 (0%) 0/4 (0%) 0/4 (0%) 0/2 (0%) 0/2 (0%) 4/4 (100%)
Note:—Gd-T1WI indicates gadolinium-diethylene triaminepentaacetic acid T1-weighted imaging; ADC, apparent diffusion coefficient; T1WI, T1-weighted imaging; T2WI, T2-weighted imaging; FLAIR, fluid-attenuated inversion recovery; DWI, diffusion-weighted imaging.